On 4/4/2017, Shares of TherapeuticsMD, Inc. (NYSEMKT:TXMD) closed at $7.61 in last trading day. After noting the initial trading entry at $8.09, it reached to a day’s high of $8.12 and moved to a day’s low of $7.54. The recent daily volume was 12.82 million as contrast to it’s an average volume of 2.3 million.
The last close of the TherapeuticsMD, Inc. stock reflects that it traded up +16.07% from its 50-day moving average of $6.56. The stock traded above +21.95% to its 200-day MA of $6.24. Furthermore, it moved lower -18.08% from its 52-week high of $9.29 and +73.35% up from $4.39, which is 52-week low of the stock.
TherapeuticsMD, Inc.’s (TXMD) moved with shift of 8.87% in the past week. Over the last three months, the shares of the company have changed 27.47% and performed 10.45% over the last six months. The stock currently has Monthly Volatility of 5.39% and Weekly Volatility of 5.33%.
April 4, 2017 TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, announced that data on TX-001HR, an investigational bio-identical hormone therapy combination of 17ß-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause, was presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida, April 1-4. The positive results of the pivotal phase 3 Replenish Trial data were featured in an oral and a poster presentation.
In the oral presentation , Rogerio Lobo, M.D., professor of Obstetrics and Gynecology and Director of the Reproductive Endocrinology Program at Columbia University, reviewed the detailed findings from the Replenish Trial, the phase 3 study that evaluated the safety and efficacy of four doses of TX-001HR. The Replenish Trial demonstrated that two doses of TX-001HR (estradiol 1 mg/progesterone 100 mg and estradiol 0.5 mg/progesterone 100 mg) achieved a statistically significant and clinically meaningful reduction in both the frequency and severity of hot flashes compared to placebo at weeks 4 and 12, meeting all the co-primary efficacy endpoints.
Secondary endpoint data presented by Dr. Lobo also showed statistically significant improvement in both total and vasomotor menopause specific quality-of-life questionnaire (MENQOL) scores at week 12 and maintained through six and 12 months for these two doses of TX-001HR, further supporting the primary efficacy data shown in the Replenish Trial. MENQOL is a validated tool used to measure quality-of-life in postmenopausal women.
Dr. Lobo commented, “I am pleased to finally see evidence from a well-controlled trial supporting the use of defined doses of bio-identical estradiol and progesterone in combination to treat VMS. These study data, including both the primary and secondary endpoints, suggest that, if approved, TX-001HR will be a valuable new treatment option for women suffering from symptoms of menopause.”
Dollar Tree, Inc. (NASDAQ:DLTR) finalized the last transaction at value of $77.67, with a daily change of -0.06% or -0.05 points. The company maintained volume of 2.19 million shares. In past trading day, the stock hit the maximum price of $77.96 and touched to minimum value of $76.90. It has a market cap of $ 18.35B.
As of last trade close, the stock is trading downside -22.28% from its one year high of $99.93 and moved +7.06% upward from $72.55, which is one year low of the stock.
The stock traded above +1.16% from its 50-day moving average of $76.78. Furthermore, the stock moved -1.35% to its 200-day MA of $ 78.73.
During the last month, Dollar Tree, Inc.’s (DLTR) has changed 2.29% and performed -2.34% over the last 6 months. The mean rating score for this stock is at 2.50. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.99% in recent month and observed Weekly Volatility of 2.15%.